Monitor the company's clinical and regulatory progress under the strengthened leadership team, particularly regarding the nPulse Cardiac Catheter Ablation System development.
Price Chart
Executive Summary
Pulse Biosciences appointed Liane Teplitsky as Chief Operating Officer and expanded Dr. David Kenigsberg's role as Chief Medical Officer to strengthen its leadership team. The company also disclosed inducement equity awards for Teplitsky and other new hires.
Key Facts
- Appointed Liane Teplitsky as Chief Operating Officer effective April 8, 2026
- Expanded Dr. David Kenigsberg's role to full-time Chief Medical Officer
- Teplitsky's employment agreement includes $525,000 annual base salary and eligibility for a 70% target bonus
- Granted inducement equity awards to Teplitsky consisting of a stock option for 700,000 shares and 200,000 restricted stock units
- Also granted inducement options to two other recently hired employees for 7,700 shares total
Financial Impact
The inducement equity awards represent potential dilution, with Teplitsky's awards valued at approximately $13.4 million based on the $19.06 per share grant price
Risk Factors
- Potential dilution from the equity inducement awards
- Integration risks with new executive leadership
- Dependence on successful development of the nPulse Cardiac Catheter System
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-011831 |
| Exhibit: ex_933283.htm | 0001437749-26-011831 |
| Document: plse20260316_8k.htm | 0001437749-26-011831 |
| Document: 0001437749-26-011831-index-headers.html | 0001437749-26-011831 |
| Document: 0001437749-26-011831-index.html | 0001437749-26-011831 |
| Document: 0001437749-26-011831.txt | 0001437749-26-011831 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $46.32 | awaiting T+60 | — | $52.66 (+13.69%) |
Oct 7, 2026 19d ago | 8-K | $49.09 | awaiting T+60 | — | $52.66 (+7.27%) |
Sep 15, 2026 5w ago | 8-K | $55.20 | awaiting T+60 | — | $52.66 (−4.60%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $52.66 (+53.75%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $52.66 (+116.09%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $52.66 (+110.72%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $52.66 (+105.62%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $52.66 (+176.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers